Getty Images
May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the lives of patients with brain tumors, today announced it has entered into a strategic distribution partnership with Theragenics Corporation (Theragenics), a global leader in minimally invasive brachytherapy. The partnership aims to expand physician access to Cesium-131 seeds, offering greater flexibility to support their brachytherapy procedural needs.
Through the partnership, Theragenics will become the exclusive distributor of Cesium-131 brachytherapy seeds and carriers used for a variety of non-brain cancer related treatments including prostate cancer. GT MedTech, the sole manufacturer of Cesium-131, will continue to focus on expanding adoption of the company’s FDA-cleared revolutionary GammaTile therapy for the treatment of operable brain tumors in the U.S.
Cesium-131 is a common isotope used with Low Dose Rate [LDR] brachytherapy, a radiation treatment where tiny radioactive seeds are implanted directly into or adjacent to a tumor. This approach delivers a high dose of radiation to cancer cells while minimizing damage to surrounding healthy tissues.
“We are very pleased to align with Theragenics, a global brachytherapy leader, to propel the field of cancer care forward.” said Per Langoe, CEO of GT Medical Technologies. “This partnership ensures continued access to Cesium-131 for clinicians and patients, addressing critical healthcare needs.”
Michael Krachon, President of Theragenics Interventional, added, “This partnership reinforces Theragenics’ unwavering commitment to brachytherapy. With the addition of Cesium-131 to our portfolio, we can more comprehensively support the clinical needs of the brachytherapy community and further expand our efforts to raise awareness of brachytherapy as a viable treatment option for men battling prostate cancer.”
As the exclusive manufacturer of Cesium-131, GT MedTech is dedicated to expanding its utilization to advance cancer care. Concurrently, GT MedTech is focused on driving the evidence-based adoption of GammaTile, aiming to establish a new standard of care for operable brain tumors.*
*See Product IFU for detailed information.
For more information: www.gtmedtech.com
April 10, 2026 
